UDP-Gal: BetaGlcNAc Beta 1,3-Galactosyltransferase, Polypeptide 5 (B3GALT5)

  • Akira TogayachiEmail author
  • Hisashi Narimatsu
Reference work entry


β3-Galactosyltransferase (β3GalT) transfers galactose from UDP-Gal to N-acetylglucosamine (GlcNAc) with a β1,3-linkage. To date, five members of the β3GalT family have been cloned and analyzed (Isshiki et al. 1999). β3GalT1 was cloned first by an expression cloning method (Sasaki et al. 1994). Three additional members, β3GalT2, β3GalT3*, and β3GalT4, which have sequences homologous to β3GalT1, were identified in the EST database and subsequently cloned (Isshiki et al. 1999; Kolbinger et al. 1998; Amado et al. 1998; Hennet et al. 1998). (*B3GALT3 was renamed B3GALNT1, since the enzymatic activity of β3GalNAcT was found in later studies.)


Long Terminal Repeat Schizoaffective Disorder Acceptor Substrate Hepatocyte Nuclear Factor Colo205 Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Amado K, Almeida R, Carneiro F, Leverly SB, Holmes EH, Nomoto M, Hollingsworth MA, Hassan H, Schwientek T, Nielsen PA, Bennett EP, Clausen H (1998) A family of human β3-galactosyltransferases. Characterization of four members of a UDP-galactose: β-N-acetylglucosamine b-N-acetylgalactosamine β-1,3-galactosyltransferase family. J Biol Chem 278:12770–12778CrossRefGoogle Scholar
  2. Caretti A, Sirchia SM, Tabano S, Zulueta A, Dall’Olio F, Trinchera M (2012) DNA methylation and histone modifications modulate the β1,3 galactosyltransferase β3Gal-T5 native promoter in cancer cells. Int J Biochem Cell Biol 44:84–90. doi:10.1016/j.biocel.2011.09.010PubMedCrossRefGoogle Scholar
  3. Dunn CA, Medstrand P, Mager DL (2003) An endogenous retroviral long terminal repeat is the dominant promoter for human beta1,3-galactosyltransferase 5 in the colon. Proc Natl Acad Sci USA 100:12841–12846PubMedCentralPubMedCrossRefGoogle Scholar
  4. Dunn CA, van de Lagemaat LN, Baillie GJ, Mager DL (2005) Endogenous retrovirus long terminal repeats as ready-to-use mobile promoters: the case of primate beta3GAL-T5. Gene 364:2–12PubMedCrossRefGoogle Scholar
  5. Griffitts JS, Whitacre JL, Stevens DE, Aroian RV (2001) Bt toxin resistance from loss of a putative carbohydrate-modifying enzyme. Science 293:860–864PubMedCrossRefGoogle Scholar
  6. Hamshere ML, Green EK, Jones IR, Jones L, Moskvina V, Kirov G, Grozeva D, Nikolov I, Vukcevic D, Caesar S, Gordon-Smith K, Fraser C, Russell E, Breen G, St Clair D, Collier DA, Young AH, Ferrier IN, Farmer A, McGuffin P, Wellcome Trust Case Control Consortium, Holmans PA, Owen MJ, O’Donovan MC, Craddock N (2009) Genetic utility of broadly defined bipolar schizoaffective disorder as a diagnostic concept. Br J Psychiatry 195:23–29. doi:10.1192/bjp.bp.108.061424PubMedCentralPubMedCrossRefGoogle Scholar
  7. Hennet T, Dinter A, Kuhnert P, Mattu TS, Rudd MP, Berger EG (1998) Genomic cloning and expression of three murine UDP-galactose: β-N-acetylglucosamine β1,3-galactosyltransferase genes. J Biol Chem 273:58–65PubMedCrossRefGoogle Scholar
  8. Holmes EH (1989) Preparative in vitro generation of lacto-series type 1 chain glycolipids catalyzed by β1-3-galactosyltransferase from human colonic adenocarcinoma Colo 205 cells. Arch Biochem Biophys 270:630–646PubMedCrossRefGoogle Scholar
  9. Isshiki S, Togayachi A, Kudo T, Nishihara S, Watanabe M, Kubota T, Kitajima M, Shiraishi N, Sasaki K, Andoh T, Narimatsu H (1999) Cloning, expression, and characterization of a novel UDP-galactose: β-N-acetylglucosamine β1,3-galactosyltransferase (β3GalT5) responsible for synthesis of type 1 chain in colorectal and pancreatic epithelia and tumor cells derived therefrom. J Biol Chem 274:12499–12507PubMedCrossRefGoogle Scholar
  10. Isshiki S, Kudo T, Nishihara S, Ikehara Y, Togayachi A, Furuya A, Shitara K, Kubota T, Watanabe M, Kitajima M, Narimatsu H (2003) Lewis type 1 antigen synthase (β3Gal-T5) is transcriptionally regulated by homeoproteins. J Biol Chem 278:36611–36620PubMedCrossRefGoogle Scholar
  11. Kolbinger F, Streiff MB, Katopodis AG (1998) Cloning of a human UDP-galactose: 2-acetamido-2-deoxy-d-glucose 3β-galactosyltransferase catalyzing the formation of type 1 chains. J Biol Chem 273:433–440PubMedCrossRefGoogle Scholar
  12. Magnani JL, Steplewski Z, Koprowski H, Ginsburg V (1983) Identification of the gastrointestinal and pancreatic cancer-associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin. Cancer Res 43:5489–5492PubMedGoogle Scholar
  13. Mare L, Trinchera M (2007) Comparative analysis of retroviral and native promoters driving expression of beta1,3-galactosyltransferase beta3Gal-T5 in human and mouse tissues. J Biol Chem 282:49–57PubMedCrossRefGoogle Scholar
  14. Nakayama T, Watanabe M, Katsumata T, Teramoto T, Kitajima M (1995) Expression of sialyl Lewis(a) as a new prognostic factor for patients with advanced colorectal carcinoma. Cancer 75:2051–2056PubMedCrossRefGoogle Scholar
  15. Narimatsu H, Iwasaki H, Nishihara S, Kimura H, Kudo T, Yamauchi Y, Hirohashi S (1996) Genetic evidence for the Lewis enzyme, which synthesizes type-1 Lewis antigens in colon tissue, and intracellular localization of the enzyme. Cancer Res 56:330–338PubMedGoogle Scholar
  16. Narimatsu H, Iwasaki H, Nakayama F, Ikehara Y, Kudo T, Nishihara S, Sugano K, Okura H, Fujita S, Hirohashi S (1998) Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res 58:512–518PubMedGoogle Scholar
  17. Salvini R, Bardoni A, Valli M, Trinchera M (2001) β1,3-Galactosyltransferase β3Gal-T5 acts on the GlcNAcβ1-3Galβ1-4GlcNAcβ1-R sugar chains of carcinoembryonic antigen and other N-linked glycoproteins and is down-regulated in colon adenocarcinomas. J Biol Chem 276:3564–3573PubMedCrossRefGoogle Scholar
  18. Sasaki K, Sasaki E, Kawashima K, Hanai N, Nishi T, Hasegawa M (1994) JP0618759, and (2001) JP3170369Google Scholar
  19. Seko A, Kataoka F, Aoki D, Sakamoto M, Nakamura T, Hatae M, Yonezawa S, Yamashita K (2009) Beta1,3-galactosyltransferases-4/5 are novel tumor markers for gynecological cancers. Tumour Biol 30:43–50. doi:10.1159/000203129PubMedCrossRefGoogle Scholar
  20. Takada A, Ohmori K, Yoneda T, Tsuyuoka K, Hasegawa A, Kiso M, Kannagi R (1993) Contribution of carbohydrate antigens sialyl Lewis A and sialyl Lewis X to adhesion of human cancer cells to vascular endothelium. Cancer Res 53:354–361PubMedGoogle Scholar
  21. Valli M, Gallanti A, Bozzaro S, Trinchera M (1998) β-1,3-galactosyltransferase and α-1,2-fucosyltransferase involved in the biosynthesis of type-1-chain carbohydrate antigens in human colon adenocarcinoma cell lines. Eur J Biochem 256:494–501PubMedCrossRefGoogle Scholar
  22. Zhou D, Berger EG, Hennet T (1999) Molecular cloning of a human UDP-galactose: GlcNAcβ1,3GalNAcβ1,3-galactosyltransferase gene encoding an O-linked core3-elongation enzyme. Eur J Biochem 263:571–576PubMedCrossRefGoogle Scholar
  23. Zhou D, Henion T, Jungalwala FB, Berger EG, Hennet T (2000) The β1,3-galactosyltransferase β3GalT-V is a stage-specific embryonic antigen-3 (SSEA-3) synthase. J Biol Chem 275:22631–22634Google Scholar

Copyright information

© Springer Japan 2014

Authors and Affiliations

  1. 1.Research Center for Medical GlycoscienceNational Institute of Advanced Industrial Science and Technology (AIST)TsukubaJapan

Personalised recommendations